An IDH1 R132H-specific immunogenic epitope was presented by major histocompatibility complex (MHC) class II molecules and induced a CD4+ TH1 response, resulting in an effective MHC class II-restricted antitumour immune response in tumours with the IDH1 R132H mutation.100 Consistent with this result, another study found that mice immunised with peptides encompassing the IDH1 mutation site showed increased survival benefit when bearing GL261 gliomas with IDH1 R132H expression but not parental GL261 gliomas. This evidence concerns the gene HLA-C and central nervous system cancer.